Agios Presents Updated Data from the Phase 1 Dose-escalation Study of Vorasidenib in Patients with IDH-mutant Non-enhancing Glioma

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Brenda Snow
Authentic Patient Voice

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach

Daniel Sontupe
Market Access